Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial

Clinical Genitourinary Cancer - United States
doi 10.1016/j.clgc.2019.03.017
Full Text
Abstract

Available in full text

Categories
OncologyUrology
Date
Authors
Publisher

Elsevier BV

Related search

First-, Second-, Third-Line Therapy for mRCC: Benchmarks for Trial Design From the IMDC

British Journal of Cancer
Cancer ResearchOncology
2014English

Second-Line-Therapie Mit Axitinib Als Referenzstandard?

Best Practice Onkologie
Oncology
2011English

PTU-071 Methotrexate Therapy for Ulcerative Colitis in the District General Hospital Setting: A Useful Second-Line Option for Patients

Gut
Gastroenterology
2014English

Second-Line Option for Colorectal Cancer

Cancer Discovery
Oncology
2015English

Are Prognostic Indices for Brain Metastases of Melanoma Still Valid in the Stereotactic Era?

Radiation Oncology
Nuclear MedicineRadiologyImagingOncology
2018English

Is Clifford’s Rule Still Valid? Affirmative Examples From Around the World

English

Still a Role for Second-Line Chemoimmunotherapy in Chronic Lymphocytic Leukemia?

Haematologica
Hematology
2018English

Is the Environmental Kuznets Curve Still Valid: A Perspective of Wicked Problems

Sustainability
DevelopmentManagementMonitoringEnvironmental ScienceRenewable EnergyEnergy EngineeringLawSustainabilityPlanningPolicyPower Technologythe EnvironmentGeography
2019English

Is in Hospital Mortality Following EVAR Still a Valid Outcome Measure?

European Journal of Vascular and Endovascular Surgery
SurgeryCardiovascular MedicineCardiology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy